Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease

Figure 4 Baseline serum levels of transforming growth factor in naïve rats and in poly-lactic acid encapsulated transforming growth factor treated rats. Blood was taken from naïve Sprague-Dawley rats (males and females, 6 per sex) before and after treatment with poly-lactic acid encapsulated transforming growth factor (TGF). Animals were treated by gavage at doses of 5, 15 or 30 mg/kg, 3 × per week for 25 d. Serum levels of TGFβ were determined by ELISA without acid activation (R&D Systems Quantikine ELISA Catalog# MB100B). Statistical significance (P ≤ 0.02) vs day 25 at 5 mg/kg vs day 25 at 30 mg/kg. All differences between day 0 pre-dose and day 25 pre-dose were significant (P ≤ 0.01). TGFβ: Transforming growth factor .